Lung Cancer Information Study (LCIS-R01)

A. for lung cancer subject: 1. Pathologically or cytologically determined non-small cell lung cancer (NSCLC) 2. Receiving either first-line, second-line, or third-line chemotherapy for advanced NSCLC. Any chemotherapy will be acceptable 3. Stage IIIB or IV 4. Performance status of KPS 60-100% or ECOG 0-2 5. Hematologic and metabolic parameters suitable for chemotherapy 6. Patients previously treated with adjuvant therapy who now have recurrent NSCLC, will be included as receiving first line therapy 7. Patients with brain metastasis are eligible provided: they are at least 1 week from completion of surgery or RT for brain metastasis, have stable and adequate neurological status to proceed with chemotherapy, and meet all other eligibility criteria 8. Patients with prior cancer diagnoses (with or without prior chemotherapy), are eligible provided the previous malignancy is well controlled 9. Ages greater than 18 with NSCLC 10. Life expectancy greater than three months 11. Able to understand English or Spanish, but is not required to be literate B.

for lung cancer subject: 1. Patients treated with molecular targeted therapy as their sole treatment 2. Patients with documented severe psychiatric diagnoses from the medical record, which may prevent full study participation 3. Patients receiving protocol chemotherapy that mandates either the number of cycles of treatment to be received or a fixed schedule of imaging studies 4. Patients receiving concomitant chemotherapy and radiation therapy are not eligible for this protocol 5. Patients who are prisoners 6. Patients who are pregnant (self reporting by patient) 7. Patients who are cognitively impaired C. Inclusion criteria for supporter: 1. Ages greater than 18 2. Able to understand English or Spanish, but is not required to be literate D.